SCHEMBL30730669

SCHEMBL30730669

Cn1ncnc1CC(=O)N1CCC(n2nnc(-c3ccc(C(F)(F)F)cc3)n2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HDAC6 Q9UBN7 2/20 0.38
HDAC4 P56524 1/20 0.38
KCNJ6 P48051 1/20 0.38
KCNJ5 P48544 1/20 0.38
KCNJ3 P48549 1/20 0.38
PKM P14618 1/20 0.38
RAB9A P51151 1/20 0.37
CTSS P25774 1/20 0.37
EGFR P00533 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
DRD3 P35462 1/20 0.37
HTT P42858 2/20 0.36
AOC3 Q16853 2/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730597 0.90 MAPK1 (0.44) LMNAALDH1A1KCNJ6KCNJ5KCNJ3
SCHEMBL30730500 0.88 DRD2 (0.41) LMNAALDH1A1PKMRAB9AMEN1
SCHEMBL30730526 0.86 KCNJ6 (0.39) LMNAALDH1A1KCNJ6KCNJ5KCNJ3
SCHEMBL30730648 0.84 CALCRL (0.40) LMNAALDH1A1KCNJ6KCNJ5KCNJ3
SCHEMBL30730675 0.83 ENPP2 (0.36) LMNAALDH1A1RAB9AMEN1KMT2A
SCHEMBL30730568 0.83 CCR3 (0.40) LMNAALDH1A1KCNJ6KCNJ5KCNJ3
SCHEMBL30730596 0.79 ENPP2 (0.42) LMNAALDH1A1HDAC6HDAC4KCNJ6
SCHEMBL30730594 0.74 MAPK1 (0.45) LMNAALDH1A1KCNJ6KCNJ5KCNJ3
SCHEMBL30730542 0.72 LMNA (0.68) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL30730562 0.71 LMNA (0.53) LMNAHTTGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 LMNA 1838/4885ALDH1A1 2154/4885HDAC6 1461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.